文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

DREPAGREFFE试验:镰状细胞贫血移植后10年脑血管结局优于标准治疗

Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial.
PubMed 文献 · Am J Hematol · 2026-05-28

DREPAGREFFE-1试验纳入67例因异常TAMMV(≥200 cm/s)接受慢性输血的镰状细胞贫血患儿,比较匹配同胞供者造血干细胞移植(MSD-HCT)与标准治疗。10年随访显示MSD-HCT组无死亡、卒中、排斥或慢性GVHD,生活质量更优,住院次数、住院天数(p<0.001)和危象(p=0.001)更少;无卒中患者狭窄评分(p=0.027)和沉默性脑梗死评分(p=0.041)下降更显著,工作记忆(p=0.016)和处理速度(p=0.011)改善而标准治疗组恶化。

要点

  • MSD-HCT组10年无死亡、卒中、排斥或慢性GVHD。
  • MSD-HCT组住院次数、住院天数(p<0.001)和危象(p=0.001)低于标准治疗。
  • 无卒中患者MSD-HCT后狭窄评分(p=0.027)和SCI评分(p=0.041)下降更显著。

核心结论

  • 镰状细胞贫血患儿接受MSD-HCT后10年脑血管结局、认知功能和生活质量优于标准治疗。
  • 研究支持对有MSD的镰状细胞贫血患儿更早考虑HCT以保护神经功能和生活质量。

研究设计与样本

  • DREPAGREFFE-1为法国多中心前瞻性试验,纳入67例(35女/32男)5-15岁因TAMMV≥200 cm/s接受慢性输血的镰状细胞贫血患儿。
  • DREPAGREFFE-2于2022年9月至2024年8月对同一67例患儿进行10年结局再评估。

主要发现

  • 两组均无死亡或卒中;MSD-HCT组(n=32)无排斥或慢性GVHD。
  • 标准治疗组(n=35)第10年时16例使用羟基脲、16例接受慢性输血、3例接受单倍体HCT。
  • MSD-HCT后生活质量更优(包括社会功能),住院次数、住院天数(p<0.001)和危象(p=0.001)低于标准治疗。
  • 无卒中患者中,MSD-HCT后狭窄评分(p=0.027)和SCI评分(p=0.041)下降显著多于标准治疗。
  • MSD-HCT后工作记忆(p=0.016)和处理速度(p=0.011)显著改善,而标准治疗组恶化。

临床怎么用

  • 对有MSD的镰状细胞贫血患儿,可更早考虑HCT以保护神经功能和生活质量。
  • 10年随访显示MSD-HCT在脑血管和认知结局方面优于标准治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard-care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE-1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard-care to match sibling donor (MSD)-HCT in 67 (35F/32M) SCA children (5-15 year) on CT for abnormal time-averaged mean maximum velocities (TAMMV ≥ 200 cm/s). Seven had a stroke history. We reported that MSD-HCT reduced the highest TAMMVs at 1- and 3-year (p < 0.001) and improved quality of life (QoL) for physical and school functioning. In stroke-free patients, the 3-year stenosis score was lower (p = 0.010). Nevertheless, no significant difference was observed for silent cerebral infarcts (SCI) and cognitive performance. This prompted us to initiate DREPAGREFFE-2 to reevaluate the outcomes at 10 years (September 2022/August 2024) with the same 67 SCA children. No death or stroke occurred in either arm. No rejection or chronic-GvHD arose in the MSD-HCT group (n = 32). In the standard-care group (n = 35), 16 were on hydroxyurea, and 16 on CT at Year 10, and 3 received haploidentical-HCT. After MSD-HCT, the QoL was better, even for social functioning, and the number of hospitalizations, hospitalized days (p < 0.001), and crises (p = 0.001) was lower than on standard-care. In stroke-free patients, stenosis (p = 0.027) and SCI scores (p = 0.041) decreased significantly more after MSD-HCT than on standard-care; working memory (p = 0.016) and processing speed (p = 0.011) improved significantly after MSD-HCT, but worsened on standard-care. These effects were not previously detected with shorter follow-up. This supports earlier consideration of HCT for SCA children with MSD to preserve neurologic function and QoL for a more productive future.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bernaudin F, Verlhac S, Ducros-Miralles E, et al. Better 10-Year Cerebrovascular Outcome After Transplant Than on Standard-Care in Sickle Cell Anemia: DREPAGREFFE Trial. Am J Hematol. 2026. PMID: 42210447. doi:10.1002/ajh.70336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。